This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Seattle Genetics' 2nd Cancer Study Win

SEATTLE ( TheStreet) -- Clinical trial victory two for Seattle Genetics' (SGEN) lymphoma drug brentuximab vedotin.

Seattle Genetics said Monday that 86% of patients with advanced systemic anaplastic large cell lymphoma (ALCL) responded to treatment with brentuximab, also known as SGN-35. The phase II study enrolled 58 ALCL patients, all of whom had a form of the rare cancer that was no longer responding to currently available therapies. This is the second positive clinical trial for brentuximab announced in as many weeks. On Sept. 27, Seattle Genetics announced positive results from a study in patients with advanced Hodgkin disease.

Seattle Genetics intends to submit brentuximab for U.S. approval in the first half of 2011 as a treatment for both forms of lymphoma. Millennium Pharmaceuticals, the U.S.-based subsidiary of the Japanese drug maker Takeda, is Seattle Genetics' ex-U.S. partner for brentuximab and will be in charge of getting the drug approved in Europe.

ALCL is an aggressive type of T-cell non-Hodgkin lymphoma that expresses a protein known as CD30. Between 2,000 and 3,000 patients are diagnosed with ALCL in the U.S. each year, with about half of those treated effectively with first-line chemotherapy.

Brentuximab is designed using a technology proprietary to Seattle Genetics that delivers a lethal dose of chemotherapy directly to cancer cells while sparing healthy cells from toxic effects. Brentuximab consists of an antibody that attaches itself to the CD30 receptor found on tumor cells. Once inside the tumor, brentuximab releases a toxic chemotherapy payload.

Seattle Genetics closed Friday at $16.77. The stock is up 38% since Sept. 27 when the positive brentuximab data in Hodgkin lymphoma was announced.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,069.49 -1.73 -0.01%
S&P 500 1,976.91 -0.89 -0.04%
NASDAQ 4,498.6730 -7.1790 -0.16%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs